Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8409-8411

  Bian, Jing ^a   Li, Bo ^b   Kou, Xian Juan ^c   Wang, Xu Na ^a   Sun, Xiao Xu ^a   Ming, Liang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c WUHAN SPORTS UNIVERSITY   (China)

Author keywords

Ovarian cancers; Protein chip; Treatment evaluation; Tumor markers

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA, MUCINOUS; AGED; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PROCEDURES; PROGNOSIS; PROTEIN MICROARRAY;

ADENOCARCINOMA, MUCINOUS; AGED; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84929213121     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8409     Document Type: Article

References (16)

1. Bian J, Li B, Kou XJ, Liu TZ, Ming L (2013). Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev, 14, 6241-3.
2. Devan SM, Pailoor J, Sthaneshwar P, Narayanan V (2013). Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels. Asian Pac J Cancer Prev, 14, 4545-8.
3. Hou JX, Yang XQ, Chen C, et al (2011). Screening the gastric cancer related tumor markers from multi-tumor markers protein chip with kappa coefficient and cost-effectiveness analysis. Hepatogastroenterology, 58, 632-6.
4. Hourigan CS, Levitsky HI (2011). Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J, 17, 309-24.
5. Khaider NG, Lane D, Matte I, Rancourt C, Piche A (2012). Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res, 2, 75-92.
6. Liang Z, Wang HF, Wu AZ, Cai JH (2010). Clinical value of multitumor markers protein biochip in the diagnosis of pulmonary carcinoma. Nan Fang Yi Ke Da Xue Xue Bao, 30, 2516-8.
7. Lin JY, Qin JB, Li XY, Dong P, Yin BD (2012). Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5427-32.
8. Meany DL, Sokoll LJ, Chan DW (2009). Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn, 3, 597-605.
9. Parikh K, Peppelenbosch MP (2010). Kinome profiling of clinical cancer specimens. Cancer Res, 70, 2575-8.
10. Rusling JF, Kumar CV, Gutkind JS, Patel V (2010). Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst, 135, 2496-511.
11. Sun Z, Fu X, Zhang L, et al (2004). A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Anticancer Res, 24, 1159-65.
12. Sundar S, Wu J, Hillaby K, Yap J, Lilford R (2012). A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol, 125, 493-9.
13. Wesolowski R, Ramaswamy B (2011). Gene expression profiling: changing face of breast cancer classification and management. Gene Expr, 15, 105-15.
14. Yang XQ, Yan L, Chen C, Hou JX, Li Y (2009). Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepatogastroenterology, 56, 1388-94.
15. Zagouri F, Dimopoulos MA, Bournakis E, Papadimitriou CA (2010). Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol, 31, 268-77.
16. Zhu H, Cox E, Qian J (2012). Functional protein microarray as molecular decathlete: a versatile player in clinical proteomics. Proteomics Clin Appl, 6, 548-62.